HLA-F Antibody (YA3943)
(Synonyms: HLAF; CDA12; HLA-5.4; HLA-CDA12)HLA-F Antibody (YA3943) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HLA-F.
-
Host:
Mouse
-
Isotype:
IgG2b
-
Application:
WB, FC, ELISA
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
Supplied in PBS with 0.05% sodium azide
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
FC
FC: Flow Cytometry
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|
| Dilution Ratio | 1:500-1:2000 | 1:200-1:400 | 1:10000 |
Product Details
HLA-F Antibody (YA3943) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HLA-F.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman, Mouse, Rat
-
Observed Molecular WeightObserved band size: 40-50 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 39 kDa
Purified recombinant fragment of human HLA-F (AA: 22-305) expressed in E. Coli.
affinity purified.
Non-conjugated
Unmodified
IgG2b
Product Properties
-
Appearance
Liquid
-
Formulation
Supplied in PBS with 0.05% sodium azide
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
HLA-F is a Non-classical major histocompatibility class Ib molecule postulated to play a role in immune surveillance, immune tolerance and inflammation. Functions in two forms, as a heterotrimeric complex with B2M/beta-2 microglobulin and a peptide (peptide-bound HLA-F-B2M) and as an open conformer (OC) devoid of peptide and B2M (peptide-free OC). In complex with B2M, presents non-canonical self-peptides carrying post-translational modifications, particularly phosphorylated self-peptides. Peptide-bound HLA-F-B2M acts as a ligand for LILRB1 inhibitory receptor, a major player in maternal-fetal tolerance. Peptide-free OC acts as a ligand for KIR3DS1 and KIR3DL2 receptors. Upon interaction with activating KIR3DS1 receptor on NK cells, triggers NK cell degranulation and anti-viral cytokine production. Through interaction with KIR3DL2 receptor, inhibits NK and T cell effector functions. May interact with other MHC class I OCs to cross-present exogenous viral, tumor or minor histompatibility antigens to cytotoxic CD8+ T cells, triggering effector and memory responses. May play a role in inflammatory responses in the peripheral nervous system. Through interaction with KIR3DL2, may protect motor neurons from astrocyte-induced toxicity[1][2][3][4][5].
-
Subcellular Localization
Cell membrane; Single-pass type I membrane protein; Early endosome membrane; Lysosome membrane
-
Expression
Tissue_specificity:Expression in resting B cells (protein level) . Expression in secondary lymphoid organs rich in B cells and T cells (such as tonsils, spleen, and thymus) (PubMed:10605026, PubMed:11169396) . Expression in tonsillar endothelial cells (PubMed:11169396) . Expression on activated lymphocytes (including B cells, NK cells, CD4+ T cells, and memory T cells) (PubMed:20865824, PubMed:27455421) . Expression in spinal motor neurons (PubMed:26928464) .
Induction:Up-regulated in CD4+ T cells upon stimulation via TCR and upon HIV-1 infection -
Isoforms & Post-Translational Modification
P30511 has 3 isomers: P30511-1: 39062 Da (predicted); P30511-2: 28588 Da (predicted); P30511-3: 50438 Da (predicted).
N-glycosylated -
Subunit
Forms a heterotrimer with B2M and a self-peptide (PubMed:28636952). Binds a diverse number of peptides ranging from 7 to more than 30 amino acids (PubMed:28636952). Peptide-bound HLA-F-B2M interacts with LILRB1 and LILRB2 but not with KIR3DS1 or KIR3DL2; this interaction is direct (PubMed:11169396, PubMed:28636952). The OC form interacts with KIR3DS1, KIR2DS4 and KIR3DL2; this interaction is direct (PubMed:24018270, PubMed:27455421, PubMed:28636952). Interacts with TAP1-TAP2 complex and CALR; this interaction is required for appropriate folding and peptide loading (PubMed:10605026, PubMed:11169396). Interacts with the coat protein complex II and 14-3-3 proteins; these interactions likely control the anterograde ER-to-Golgi transport of HLA-F (PubMed:16709803). HLA-F-B2M complex interacts with the heavy chain of other MHC class I molecules including HLA-A and HLA-E; this interaction may regulate the intracellular trafficking and the stability of peptide-free MHC class I OCs (PubMed:20483783)
-
SwissProt ID
-
Synonyms
HLAF; CDA12; HLA-5.4; HLA-CDA12
Documentation